Using a Continuous Glucose Monitor on a GLP-1 During Menopause

A continuous glucose monitor (CGM) is a small sensor worn on the back of the upper arm with a filament sitting just under the skin. It measures glucose in the fluid between your cells — not in your blood directly — and sends a reading to your phone every few minutes. Because it samples interstitial fluid, readings lag actual blood glucose by roughly 5 to 15 minutes, which matters when you are watching a curve move in real time.

Until recently, CGMs required a prescription and a diabetes diagnosis. That changed with FDA clearance of over-the-counter devices. As of 2026, Dexcom Stelo and Abbott Lingo are the two OTC CGMs commercially available in the US. Abbott Libre Rio received FDA clearance in June 2024 but had not fully launched commercially in the US as of early 2026.

The two available devices differ in ways worth knowing. Stelo is built on Dexcom's G7 platform and wears for 15 days per sensor. Lingo uses a 14-day sensor and is priced from around $49 for a single sensor up to $249 for a 12-week subscription. Lingo has a notable limitation for anyone using it diagnostically: its display range is capped, so readings above roughly 200 mg/dL or below 55 mg/dL flatline rather than showing the true value.

Neither device is intended for people who use insulin, and neither replaces medical monitoring for diagnosed diabetes. They are marketed as wellness and metabolic-awareness tools, which is a useful framing for the purpose in this article — you are gathering information about yourself, not managing a disease.

It gets harder to manage, and not simply because of weight gain.

Estrogen has direct effects on glucose metabolism. It supports insulin sensitivity in muscle and liver tissue, influences where the body stores fat, and affects pancreatic beta cell function. As estrogen declines through perimenopause and into postmenopause, insulin resistance — the state where cells respond less efficiently to insulin, so the pancreas has to produce more of it — tends to increase.

The SWAN study (Study of Women's Health Across the Nation) has followed a large, ethnically diverse cohort of women through the menopause transition since 1996, and it is the best longitudinal evidence available on this. SWAN data show increases in insulin resistance and adverse changes in metabolic markers across the transition, and importantly these changes are not fully explained by aging or by weight gain alone. The hormonal shift appears to contribute independently.

There is also a body composition change happening simultaneously. Fat storage shifts from the hips and thighs toward the abdomen, and specifically toward visceral fat — the metabolically active fat that surrounds internal organs. Visceral fat is more strongly associated with insulin resistance than subcutaneous fat, so where weight sits matters as much as how much of it there is.

And then there is sleep. Night sweats and menopausal insomnia fragment sleep, and even short-term sleep restriction measurably reduces insulin sensitivity in controlled studies. This creates a loop where poor sleep worsens glucose control, which does nothing good for sleep quality.

Our article on [metabolic syndrome in menopause and the SWAN data](/blog/metabolic-syndrome-in-menopause-swan-data-explained) goes deeper into the numbers, and [perimenopause weight gain](/blog/perimenopause-weight-gain-why-it-happens-swan-data) covers the body composition side.

Dramatically — and this is the single most important thing to understand before you interpret a single reading.

GLP-1 medications lower post-meal glucose through three mechanisms working together. They slow gastric emptying, so food arrives in the small intestine more gradually and glucose enters the bloodstream over a longer window. They enhance glucose-dependent insulin secretion, meaning the pancreas releases insulin more effectively when glucose is actually rising. And they suppress glucagon, the hormone that tells the liver to release stored glucose.

The visible result on a CGM is a flatter curve. Meals that would previously have produced a sharp rise and fall now produce a gentle, broad bump — sometimes so broad that you cannot clearly see where one meal ends and the next begins. Peak values are lower and arrive later.

This creates an interpretation trap. If you start wearing a CGM after you are already established on a GLP-1, you may conclude that a particular food is fine for you when in fact the medication is masking a response that would appear without it. That matters if you ever pause or stop the medication. It also matters for the common use case of 'finding my trigger foods' — the drug reduces the signal you are trying to detect.

There is a second wrinkle. Because gastric emptying is slowed, the timing of any glucose rise shifts later, sometimes by an hour or more. A reading taken at the conventional two-hour post-meal mark may catch you before the peak rather than after it. If you are comparing your numbers to standard post-meal targets, you may be measuring the wrong moment entirely.

Our explainer on [how GLP-1s affect cholesterol and lipids in menopause](/blog/glp1-and-cholesterol-in-menopause-what-happens-to-your-lipids) covers a parallel version of this — medication effects reshaping the markers you are tracking.

Less than the apps suggest, and this is where most people go wrong.

For reference, a healthy person without diabetes typically spends 95% or more of a two-week CGM wear within the standard target range, with fasting glucose in the roughly 70 to 100 mg/dL band and post-meal peaks that return toward baseline within two to three hours. Brief excursions after a large or carbohydrate-heavy meal are entirely normal physiology, not a warning sign.

The common misinterpretations are worth naming. A spike after a meal is not damage — glucose rising after eating is the system working. A single high reading is not a diagnosis — sensor accuracy is good but not perfect, compression from lying on the sensor produces false lows, and the first 12 to 24 hours after insertion are the least reliable. And individual variation is large — two people can eat the same meal and produce very different curves for reasons that have nothing to do with health status.

The metrics that actually carry information over a two-week wear are: your average glucose and how it compares to your last HbA1c, your fasting or overnight baseline (which is more informative than any single post-meal number), how quickly you return to baseline after eating, and your overall variability — a consistently jagged trace suggests something worth investigating more than one tall peak does.

One honest caveat from the research: there is no evidence that ongoing CGM use changes health outcomes for someone who is metabolically healthy. The devices are legitimate hardware for a short glucose audit. As a permanent subscription for a non-diabetic user, they have not been shown to improve anything except awareness — which sometimes helps and sometimes becomes a source of anxiety.

Used as a defined experiment rather than a permanent feed, a two-week wear can answer several questions that are hard to answer any other way.

Do night sweats correspond to glucose dips? Some women experience overnight hypoglycemia-like symptoms — waking hot, sweaty, and anxious at 3am — that are indistinguishable from vasomotor symptoms. A CGM can show whether your glucose is genuinely dropping overnight or whether the wake-ups are purely hormonal. This changes what you do about it.

Is your evening meal timing working against your sleep? Late, large, carbohydrate-heavy dinners produce glucose patterns overnight that some people find correlate with worse sleep. Seeing it makes the change easier to sustain than being told about it.

Is your protein-forward eating actually protein-forward? Many people on a GLP-1 believe they are eating high-protein meals that are in practice carbohydrate-dominant. A CGM trace makes the composition visible in a way that self-report does not. Our guide to [protein needs on a GLP-1 during menopause](/blog/protein-needs-on-glp1-during-menopause-prevent-muscle-loss) covers what the target should be.

What does exercise do for you specifically? The glucose-lowering effect of a walk after eating is one of the most reliably visible things on a CGM, and seeing your own curve flatten after 15 minutes of walking is more persuasive than any study. See [walking on a GLP-1](/blog/walking-on-glp1-how-much-and-why-it-works).

Is fasting helping or stressing you? If you are experimenting with time-restricted eating, a CGM shows whether your overnight and morning readings stay stable or whether you are producing a stress-driven rise. Our piece on [intermittent fasting on a GLP-1 during menopause](/blog/intermittent-fasting-on-glp1-during-menopause-safe-or-risky) covers the risks worth knowing first.

There are real downsides, and they are not evenly distributed.

The clearest is disordered eating risk. A device that assigns a continuous, quantified score to everything you eat is a poor fit for anyone with a history of restrictive eating, orthorexia, or obsessive food tracking. GLP-1 use already restructures your relationship with food substantially. Layering real-time numerical feedback on top can convert a helpful awareness tool into a source of guilt and avoidance. If food already occupies more mental space than you would like, this is not the intervention for you.

The second is anxiety amplification. Menopause itself elevates anxiety for many women, and a stream of numbers with no clinical context is fertile ground for worry. A reading of 145 after lunch means very little in isolation, but at 2am it can feel like evidence of something serious.

The third is cost with unclear return. A subscription runs to several hundred dollars a year. For a metabolically healthy person, that money buys awareness rather than measured health improvement. There is nothing wrong with paying for awareness — but it is worth naming what you are buying.

The fourth is acting on noise. Sensor readings drift, compression lows are common, and hydration and temperature affect interstitial readings. Restricting entire food groups based on one unusual trace is a bad trade.

And one clinical note: if you are having symptoms that suggest genuine hypoglycemia — shakiness, sweating, confusion, or palpitations that resolve with eating — that warrants a medical evaluation with proper blood testing, not a consumer sensor. This is particularly relevant if you take a GLP-1 alongside insulin or a sulfonylurea, where true hypoglycemia is a real possibility.

Our article on [health anxiety in menopause](/blog/health-anxiety-in-menopause-why-you-fear-the-worst) is worth reading if you recognize yourself in the second paragraph above.

For most women in menopause on a GLP-1, a handful of unglamorous measures carry more decision-making value than continuous glucose data.

HbA1c, a blood test reflecting average glucose over roughly three months, remains the standard for assessing glucose control and requires one blood draw rather than a wearable. Fasting insulin alongside fasting glucose allows calculation of HOMA-IR, a useful marker of insulin resistance that a CGM cannot give you. Waist circumference is a crude but genuinely predictive proxy for visceral fat, and it costs nothing. Blood pressure and a lipid panel complete the metabolic picture, and both change meaningfully during the menopause transition — see [why LDL rises after 45](/blog/menopause-and-cholesterol-why-ldl-rises-after-45).

On the muscle side, grip strength is a cheap, validated measure that tells you whether you are preserving lean mass while losing weight — arguably the most important thing to monitor on a GLP-1 in midlife. Our piece on [grip strength as a muscle marker](/blog/grip-strength-on-glp1-the-muscle-marker-that-matters) explains how to test it.

The honest summary is this. A CGM is an interesting and increasingly affordable window into your own physiology, and a focused two-week wear can produce two or three genuinely useful behavior changes. It is not a health intervention in itself, and on a GLP-1 it is measuring a system the medication is already actively reshaping. Use it as a curiosity-driven experiment with a defined end date, take the two or three lessons that replicate, and put the money toward protein, weights, and sleep — which have far better evidence behind them than any wearable.

If you want a broader view of how your medications interact through the day, our [midlife medicine cabinet timing guide](/blog/glp1-hrt-statins-midlife-medicine-cabinet-timing-guide) covers the practical sequencing.